Background

Naveen Rao is an independent neurotechnology industry analyst, writer, and ecosystem builder. He studied biology and public health at Johns Hopkins and has worked as a healthcare analyst for approximately 19 years before focusing on the neurotechnology category. He is a Forbes contributor and advises public and private interests on bringing next-generation neurotechnology into society responsibly.

Neurotech Futures

Rao is the founder and publisher of Neurotech Futures, an independent research and analysis platform covering the brain-computer interface and broader neurotechnology industry. The publication is widely regarded as the leading independent industry newsletter in the sector, with thousands of subscribers including investors, founders, journalists, and researchers.

Neurotech Notables

Rao publishes the Neurotech Notables Substack on a biweekly cadence. The series tracks funding rounds, regulatory milestones, clinical trial events, conference signals, capital cluster patterns, and policy developments across the BCI and bioelectronic-medicine industry. Notables is one of the most-cited independent industry sources in BCI press, and is regularly referenced as a primary lens on the sector.

Rao also publishes annual neurotech funding snapshots through Neurotech Futures, breaking down deal flow across implanted BCI, transcranial neuromodulation, focused ultrasound, consumer neurotech, neuroAI, cognitive assessments, and non-invasive devices. His 2024 snapshot tracked $2.3 billion across 129 deals across the broader neurotech category.

Perspective

Rao’s core thesis is summarised in his recurring frame: “brain health is human health.” Neurotechnology, in his analysis, is not a niche medical device category but a foundational platform that will reshape commerce, healthcare delivery, and the operating assumptions of the AI era. He has consistently argued that the BCI industry’s commercial trajectory will be determined by the alignment of clinical readouts, payer reimbursement architecture, and capital patience — and that the industry’s narrative leadership currently sits with a small number of independent voices working outside the venture-backed company structure that dominates US BCI coverage.